Liver auto-immunology: The paradox of autoimmunity in a tolerogenic organ

Journal of Autoimmunity

Volumn 46, Issue , 2013, Pages 1-6

  Invernizzi, Pietro ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmunity; Liver immunology

Indexed keywords

CYTOCHROME P450; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN G4; STAT4 PROTEIN; URSODEOXYCHOLIC ACID;

ADAPTIVE IMMUNITY; APOPTOSIS; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; AUTOIMMUNITY; CELL PROLIFERATION; CHRONIC LIVER DISEASE; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; HEREDITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE FLORA; KUPFFER CELL; LIVER FUNCTION; LIVER STRUCTURE; LYMPHOID CELL; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SJOEGREN SYNDROME;

AUTOIMMUNITY; LIVER IMMUNOLOGY;

ANTIGEN-PRESENTING CELLS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BILIARY TRACT; GASTROINTESTINAL TRACT; HUMANS; IMMUNE TOLERANCE; LIVER; LIVER DISEASES; MODELS, IMMUNOLOGICAL;

EID: 84886289571     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.08.006     Document Type: Review

References (102)

1. Bogdanos D.P., Gao B., Gershwin M.E. Liver immunology. Compr Physiol 2013, 3:567-598.
2. Kita H., Mackay I.R., Van De Water J., Gershwin M.E. The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 2001, 120:1485-1501.
3. Lohse A.W., Weiler-Normann C., Tiegs G. Immune-mediated liver injury. JHepatol 2010, 52:136-144.
4. Tiegs G., Lohse A.W. Immune tolerance: what is unique about the liver. JAutoimmun 2010, 34:1-6.
5. Bottcher J.P., Knolle P.A., Stabenow D. Mechanisms balancing tolerance and immunity in the liver. Dig Dis 2011, 29:384-390.
6. Parker G.A., Picut C.A. Immune functioning in non lymphoid organs: the liver. Toxicol Pathol 2012, 40:237-247.
7. Starzl T.E., Marchioro T.L., Vonkaulla K.N., Hermann G., Brittain R.S., Waddell W.R. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963, 117:659-676.
8. Cantor H.M., Dumont A.E. Hepatic suppression of sensitization to antigen absorbed into the portal system. Nature 1967, 215:744-745.
9. Calne R.Y., Sells R.A., Pena J.R., Davis D.R., Millard P.R., Herbertson B.M., et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969, 223:472-476.
10. Bernal W., Auzinger G., Dhawan A., Wendon J. Acute liver failure. Lancet 2010, 376:190-201.
11. Schuppan D., Afdhal N.H. Liver cirrhosis. Lancet 2008, 371:838-851.
12. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255.
13. Dienstag J.L. Hepatitis B virus infection. NEngl J Med 2008, 359:1486-1500.
14. Rosen H.R. Clinical practice. Chronic hepatitis C infection. NEngl J Med 2011, 364:2429-2438.
15. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. NEngl J Med 2000, 343:1467-1476.
16. Lucey M.R., Mathurin P., Morgan T.R. Alcoholic hepatitis. NEngl J Med 2009, 360:2758-2769.
17. Invernizzi P., Mackay I.R. Autoimmune liver diseases. World J Gastroenterol 2008, 14:3290-3291.
18. Nemeth E., Baird A.W., O'Farrelly C. Microanatomy of the liver immune system. Semin Immunopathol 2009, 31:333-343.
19. Yokomori H., Oda M., Yoshimura K., Hibi T. Recent advances in liver sinusoidal endothelial ultrastructure and fine structure immunocytochemistry. Micron 2012, 43:129-134.
20. DeLeve L.D. Liver sinusoidal endothelial cells and liver regeneration. JClin Invest 2013, 123:1861-1866.
21. Yin C., Evason K.J., Asahina K., Stainier D.Y. Hepatic stellate cells in liver development, regeneration, and cancer. JClin Invest 2013, 123:1902-1910.
22. Coombes J.L., Robey E.A. Dynamic imaging of host-pathogen interactions invivo. Nat Rev Immunol 2010, 10:353-364.
23. Crispe I.N. Liver antigen-presenting cells. JHepatol 2011, 54:357-365.
24. Thomson A.W., Knolle P.A. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010, 10:753-766.
25. Sumpter T.L., Abe M., Tokita D., Thomson A.W. Dendritic cells, the liver, and transplantation. Hepatology 2007, 46:2021-2031.
26. Lleo A., Invernizzi P. Apotopes and innate immune system: novel players in the primary biliary cirrhosis scenario. Dig Liver Dis 2013, 45:630-636.
27. Schulz C., Gomez Perdiguero E., Chorro L., Szabo-Rogers H., Cagnard N., Kierdorf K., et al. Alineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012, 336:86-90.
28. Sica A., Mantovani A. Macrophage plasticity and polarization: invivo veritas. JClin Invest 2012, 122:787-795.
29. Lleo A., Bowlus C.L., Yang G.X., Invernizzi P., Podda M., Van de Water J., et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 2010, 52:987-998.
30. Tang X.Z., Jo J., Tan A.T., Sandalova E., Chia A., Tan K.C., et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. JImmunol 2013, 190:3142-3152.
31. Longhi M.S., Ma Y., Mieli-Vergani G., Vergani D. Regulatory T cells in autoimmune hepatitis. JHepatol 2012, 57:932-933.
32. Longhi M.S., Hussain M.J., Kwok W.W., Mieli-Vergani G., Ma Y., Vergani D. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2011, 53:536-547.
33. Bernuzzi F., Fenoglio D., Battaglia F., Fravega M., Gershwin M.E., Indiveri F., et al. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. JAutoimmun 2010, 35:176-180.
34. Fenoglio D., Bernuzzi F., Battaglia F., Parodi A., Kalli F., Negrini S., et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev 2012, 12:300-304.
35. Invernizzi P. Geoepidemiology of autoimmune liver diseases. JAutoimmun 2010, 34:J300-J306.
36. Smyk D.S., Orfanidou T., Invernizzi P., Bogdanos D.P., Lenzi M. Vitamin D in autoimmune liver disease. Clin Res Hepatol Gastroenterol 2013, 10.1016/j.clinre.2013.05.016.
37. Gershwin M.E., Mackay I.R. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 2008, 47:737-745.
38. Hirschfield G.M., Karlsen T.H., Lindor K.D., Adams D.H. Primary sclerosing cholangitis. Lancet 2013, 10.1016/S0140-6736(13)60096-3.
39. Invernizzi P., Selmi C., Gershwin M.E. Update on primary biliary cirrhosis. Dig Liver Dis 2010, 42:401-408.
40. Lohse A.W., Mieli-Vergani G. Autoimmune hepatitis. JHepatol 2011, 55:171-182.
41. Krawitt E.L. Autoimmune hepatitis. NEngl J Med 2006, 354:54-66.
42. Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis. NEngl J Med 2005, 353:1261-1273.
43. Manns M.P. Immunoglobulin G4-associated cholangitis: dominating immunoglobulin G4-positive clones within the B-cell receptor repertoire indicate light at the end of a long tunnel. Hepatology 2013, 57:2110-2113.
44. Maillette de Buy Wenniger L.J., Doorenspleet M.E., Klarenbeek P.L., Verheij J., Baas F., Elferink R.P., et al. Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology 2013, 57:2390-2398.
45. Rust C., Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008, 14:3368-3373.
46. Selmi C., Lu Q., Humble M.C. Heritability versus the role of the environment in autoimmunity. JAutoimmun 2012, 39:249-252.
47. Selmi C., Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., et al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. JAutoimmun 2012, 39:272-284.
48. Liu X., Invernizzi P., Lu Y., Kosoy R., Bianchi I., Podda M., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010, 42:658-660.
49. Invernizzi P., Ransom M., Raychaudhuri S., Kosoy R., Lleo A., Shigeta R., et al. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. Genes Immun 2012, 13:461-468.
50. Kar S.P., Seldin M.F., Chen W., Lu E., Hirschfield G.M., Invernizzi P., et al. Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes Immun 2013, 14:179-186.
51. Juran B.D., Hirschfield G.M., Invernizzi P., Atkinson E.J., Li Y., Xie G., et al. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet 2012, 21:5209-5221.
52. Invernizzi P. Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving. Hepatology 2011, 54:714-723.
53. Hirschfield G.M., Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis 2011, 31:147-156.
54. Liu J.Z., Almarri M.A., Gaffney D.J., Mells G.F., Jostins L., Cordell H.J., et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet 2012, 44:1137-1141.
55. Mells G.F., Floyd J.A., Morley K.I., Cordell H.J., Franklin C.S., Shin S.Y., et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011, 43:329-332.
56. Karlsen T.H., Franke A., Melum E., Kaser A., Hov J.R., Balschun T., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010, 138:1102-1111.
57. Liu J.Z., Hov J.R., Folseraas T., Ellinghaus E., Rushbrook S.M., Doncheva N.T., et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013, 45:670-675.
58. Naess S., Shiryaev A., Hov J.R., Franke A., Karlsen T.H. Genetics in primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol 2012, 36:325-333.
59. Hirschfield G.M., Chapman R.W., Karlsen T.H., Lammert F., Lazaridis K.N., Mason A.L. The genetics of complex cholestatic disorders. Gastroenterology 2013, 144:1357-1374.
60. Invernizzi P., Lleo A., Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis 2007, 27:161-172.
61. Wesierska-Gadek J., Penner E., Battezzati P.M., Selmi C., Zuin M., Hitchman E., et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006, 43:1135-1144.
62. Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008, 14:3374-3387.
63. Liu H., Norman G.L., Shums Z., Worman H.J., Krawitt E.L., Bizzaro N., et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. JAutoimmun 2010, 35:436-442.
64. Invernizzi P., Bossuyt X., Bogdanos D.P. Serum autoantibodies: from identification to clinical relevance. Clin Dev Immunol 2013, 2013:382069.
65. Invernizzi P., Selmi C., Ranftler C., Podda M., Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005, 25:298-310.
66. Miyake Y., Yamamoto K. Role of gut microbiota in liver diseases. Hepatol Res 2013, 43:139-146.
67. Folseraas T., Melum E., Franke A., Karlsen T.H. Genetics in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2011, 25:713-726.
68. Rudolph G., Gotthardt D., Kloters-Plachky P., Kulaksiz H., Rost D., Stiehl A. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. JHepatol 2009, 51:149-155.
69. Terjung B., Spengler U., Sauerbruch T., Worman H.J. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000, 119:310-322.
70. Terjung B., Sohne J., Lechtenberg B., Gottwein J., Muennich M., Herzog V., et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010, 59:808-816.
71. Bogdanos D.P., Baum H., Grasso A., Okamoto M., Butler P., Ma Y., et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. JHepatol 2004, 40:31-39.
72. Bogdanos D.P., Baum H., Okamoto M., Montalto P., Sharma U.C., Rigopoulou E.I., et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 2005, 42:458-465.
73. Selmi C., Balkwill D.L., Invernizzi P., Ansari A.A., Coppel R.L., Podda M., et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003, 38:1250-1257.
74. Han Y., Glaser S., Meng F., Francis H., Marzioni M., McDaniel K., et al. Recent advances in the morphological and functional heterogeneity of the biliary epithelium. Exp Biol Med (Maywood) 2013, 238:549-565.
75. Eaton J.E., Talwalkar J.A., Lazaridis K.N., Gores G.J., Lindor K.D. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013, 145:521-536.
76. Selmi C., Meroni P.L., Gershwin M.E. Primary biliary cirrhosis and Sjogren's syndrome: autoimmune epithelitis. JAutoimmun 2012, 39:34-42.
77. Nezos A., Papageorgiou A., Fragoulis G., Ioakeimidis D., Koutsilieris M., Tzioufas A.G., et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. JAutoimmun 2013, 10.1016/j.jaut.2013.04.005.
78. Barrera M.J., Bahamondes V., Sepulveda D., Quest A.F., Castro I., Cortes J., et al. Sjogren's syndrome and the epithelial target: a comprehensive review. JAutoimmun 2013, 42:7-18.
79. Yao Y., Liu Z., Jallal B., Shen N., Ronnblom L. Type I interferons in Sjogren's syndrome. Autoimmun Rev 2013, 12:558-566.
80. Castro I., Sepulveda D., Cortes J., Quest A.F., Barrera M.J., Bahamondes V., et al. Oral dryness in Sjogren's syndrome patients. Not just a question of water. Autoimmun Rev 2013, 12:567-574.
81. Gliozzi M., Greenwell-Wild T., Jin W., Moutsopoulos N.M., Kapsogeorgou E., Moutsopoulos H.M., et al. Alink between interferon and augmented plasmin generation in exocrine gland damage in Sjogren's syndrome. JAutoimmun 2013, 40:122-133.
82. Thabet Y., Le Dantec C., Ghedira I., Devauchelle V., Cornec D., Pers J.O., et al. Epigenetic dysregulation in salivary glands from patients with primary Sjogren's syndrome may be ascribed to infiltrating B cells. JAutoimmun 2013, 41:175-181.
83. Cornec D., Devauchelle-Pensec V., Tobon G.J., Pers J.O., Jousse-Joulin S., Saraux A. Bcells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment. JAutoimmun 2012, 39:161-167.
84. Guellec D., Cornec D., Jousse-Joulin S., Marhadour T., Marcorelles P., Pers J.O., et al. Diagnostic value of labial minor salivary gland biopsy for Sjogren's syndrome: a systematic review. Autoimmun Rev 2013, 12:416-420.
85. Amador-Patarroyo M.J., Arbelaez J.G., Mantilla R.D., Rodriguez-Rodriguez A., Cardenas-Roldan J., Pineda-Tamayo R., et al. Sjogren's syndrome at the crossroad of polyautoimmunity. JAutoimmun 2012, 39:199-205.
86. Singh N., Cohen P.L. Tcell in Sjogren's syndrome: force majeure, not spectateur. JAutoimmun 2012, 39:229-233.
87. Mavragani C.P., Fragoulis G.E., Moutsopoulos H.M. Endocrine alterations in primary Sjogren's syndrome: an overview. JAutoimmun 2012, 39:354-358.
88. Bournia V.K., Vlachoyiannopoulos P.G. Subgroups of Sjogren syndrome patients according to serological profiles. JAutoimmun 2012, 39:15-26.
89. Seror R., Bootsma H., Bowman S.J., Dorner T., Gottenberg J.E., Mariette X., et al. Outcome measures for primary Sjogren's syndrome. JAutoimmun 2012, 39:97-102.
90. Tzioufas A.G., Vlachoyiannopoulos P.G. Sjogren's syndrome: an update on clinical, basic and diagnostic therapeutic aspects. JAutoimmun 2012, 39:1-3.
91. Guerrier T., Le Pottier L., Devauchelle V., Pers J.O., Jamin C., Youinou P. Role of Toll-like receptors in primary Sjogren's syndrome with a special emphasis on B-cell maturation within exocrine tissues. JAutoimmun 2012, 39:69-76.
92. Abdulahad W.H., Kroese F.G., Vissink A., Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. JAutoimmun 2012, 39:103-111.
93. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. JAutoimmun 2012, 39:4-8.
94. Pavlakis P.P., Alexopoulos H., Kosmidis M.L., Mamali I., Moutsopoulos H.M., Tzioufas A.G., et al. Peripheral neuropathies in Sjogren's syndrome: a critical update on clinical features and pathogenetic mechanisms. JAutoimmun 2012, 39:27-33.
95. Manoussakis M.N., Tsinti M., Kapsogeorgou E.K., Moutsopoulos H.M. The salivary gland epithelial cells of patients with primary Sjogren's syndrome manifest significantly reduced responsiveness to 17beta-estradiol. JAutoimmun 2012, 39:64-68.
96. Konttinen Y.T., Fuellen G., Bing Y., Porola P., Stegaev V., Trokovic N., et al. Sex steroids in Sjogren's syndrome. JAutoimmun 2012, 39:49-56.
97. Brito-Zeron P., Retamozo S., Gandia M., Akasbi M., Perez-De-Lis M., Diaz-Lagares C., et al. Monoclonal gammopathy related to Sjogren syndrome: a key marker of disease prognosis and outcomes. JAutoimmun 2012, 39:43-48.
98. Ice J.A., Li H., Adrianto I., Lin P.C., Kelly J.A., Montgomery C.G., et al. Genetics of Sjogren's syndrome in the genome-wide association era. JAutoimmun 2012, 39:57-63.
99. Barrera M.J., Sanchez M., Aguilera S., Alliende C., Bahamondes V., Molina C., et al. Aberrant localization of fusion receptors involved in regulated exocytosis in salivary glands of Sjogren's syndrome patients is linked to ectopic mucin secretion. JAutoimmun 2012, 39:83-92.
100. Baldini C., Talarico R., Tzioufas A.G., Bombardieri S. Classification criteria for Sjogren's syndrome: a critical review. JAutoimmun 2012, 39:9-14.
101. Invernizzi P., Gershwin M.E. The genetics of human autoimmune disease. JAutoimmun 2009, 33:290-299.
102. Segal B.M., Nazmul-Hossain A.N., Patel K., Hughes P., Moser K.L., Rhodus N.L. Genetics and genomics of Sjogren's syndrome: research provides clues to pathogenesis and novel therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011, 111:673-680.